Business
CareDx Applauds District Court Decision to Uphold Jury Verdict that Natera Falsely Advertised its Prospera Transplant Test
Decision Reinforces CareDx Commitment to Patients by Defending Clinical Data Integrity and Reaffirms that Natera Intentionally Falsely Advertised to the
About this update from Caredx, Inc.
[{"type":"text","content":"\nDecision Reinforces CareDx Commitment to Patients by Defending Clinical Data Integrity and Reaffirms that Natera Intentionally Falsely Advertised to the Transplant Community\n\n\n BRISBANE, Calif.--(BUSINESS WIRE)--\nCareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the United States District Court for the District of Delaware (the “District Court”) decision upheld and reaffirmed the March 2022 jury verdict finding that Natera (Nasdaq: NTRA) violated the Lanham Act by falsely advertising the scientific performance of its Prospera transplant test.\n\n\nAt the conclusion of the March 2022 trial, the jury found that Natera intentionally and recklessly misled the transplant community by deliberately engaging in false advertising in the promotion and marketing of its Prospera kidney transplant rejection assessment test. On July 17, 2023, the District Court upheld the jury’s prior decision on all of the nine counts, and where the jury found that Natera made false advertising claims about its Prospera kidney transplant test and false advertising comparisons to CareDx’s AlloSure® Kidney.\n\n\nAll of the following claims were found to be FALSE ADVERTISING by Natera about its Prospera test:\n\n\n\nFALSE CLAIM: More sensitive and specific\n\n\n\nFALSE CLAIM: Better performance in correctly classifying patients with active rejection\n\n\n\nFALSE CLAIM: Superior data in detection of clinical and subclinical rejection\n\n\n\nFALSE CLAIM: Superior analytical performance\n\n\n\nFALSE CLAIM: 3x fewer rejections missed\n\n\n\nFALSE CLAIM: Lower risk of missing active rejection\n\n\n\nFALSE CLAIM: Stronger test performance with unique capabilities\n\n\n\nFALSE CLAIM: Unparalleled precision\n\n\n\nFALSE CLAIM: Highly sensitive across a range of rejection types and patients\n\n\n\nFor the full verdict form with the complete false advertising claims, go here:\n\n\nIn March 2022, a jury found that Natera intentionally and recklessly misled the transplant community by deliberately engaging in false advertising in the promotion and marketing of its Prospera kidney transplant rejection assessment test. Overwhelming evidence emerged at trial that demonstrated that Nat...